推荐产品
等级
pharmaceutical primary standard
API类
acitretin
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C
InChI
1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
InChI key
IHUNBGSDBOWDMA-AQFIFDHZSA-N
基因信息
human ... RARA(5914) , RARB(5915) , RARG(5916) , RXRA(6256) , RXRB(6257) , RXRG(6258)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Acitretin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Acitretin Capsules
生化/生理作用
合成维甲酸，是依曲甲酸酯的代谢物。 优先与细胞视黄酸结合蛋白（CRABP） 结合。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Lauren K Dunn et al.
Journal of drugs in dermatology : JDD, 10(7), 772-782 (2011-07-02)
Acitretin is a systemic retinoid drug used in the treatment of severe psoriasis. It has also been used for a spectrum of other difficult-to-treat dermatoses, including hyperkeratotic and inflammatory dermatoses and non-melanoma skin cancers. Here we review the available data
Taru Garg et al.
Dermatology online journal, 17(5), 3-3 (2011-06-04)
Linear porokeratosis is a rare disorder of keratinization that usually presents at birth. We report a 17-year-old male with generalized linear porokeratosis, a very rare variant of porokeratosis, with extensive involvement of the trunk and extremities along with nail and
Christoffer Ingves et al.
Scandinavian journal of plastic and reconstructive surgery and hand surgery, 37(5), 293-295 (2003-12-03)
We report the successful outcome of treatment of a basal cell carcinoma (BCC) with topical imiquimod and systemic acitretin in a 48-year-old woman. We think that this treatment is a possible option for management of these non-life-threatening tumours. Experimental evidence
Alessandro Borghi et al.
Acta dermato-venereologica, 95(3), 332-336 (2014-07-01)
The efficacy and safety of acitretin was evaluated retrospectively in a cohort of 46 patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) range 10-42). Patients were treated at an initial dose of 10 mg/day acitretin
British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.
A D Ormerod et al.
The British journal of dermatology, 162(5), 952-963 (2010-04-29)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门